UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa

The abstracts have been accepted as one late-breaking oral platform presentation and seven posters, including three with oral presentations.